Nuvation Bio Inc - Ordinary Shares - Class A

NYSE:NUVB  
2.46
+0.09 (+3.80%)
Products

Nuvation Bio Announces FDA Partial Clinical Hold For Phase 1 Study Of Nuv-422 In Solid Tumors

Published: 06/27/2022 11:14 GMT
Nuvation Bio Inc - Ordinary Shares - Class A (NUVB) - Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of Nuv-422 in Solid Tumors.
Nuvation Bio - Following Emergence of Uveitis, in Certain Patients Receiving Nuv-422, Company Proactively Paused Enrollment of New Patients.
Nuvation Bio Inc - While Partial Hold is in Place, No New Patients Will Be Enrolled in Nuv-422 Program.
Nuvation Bio Inc - Current Study Participants May Continue to Be Treated in Phase 1 Study.